

03/00/62
U.S. PTO
03/00/62
U.S. PTO

3-31-00

A/Box 560
Docket No. 57155-D/JPW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

HON. COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

March 29, 2000

S I R:

Transmitted herewith for filing are the specification and claims of the patent application of:

Christophe P.G. Gerald, Kenneth A. Jones, James A. Bonini, Beth E. Borowsky, and for
Inventor(s) Douglas A. Craig

DNA Encoding Mammalian Neuropeptide FF (NPFF) Receptors and Uses Thereof

Title of Invention

Also enclosed are:

33 sheet(s) of informal formal drawings.

Oath or declaration of Applicant(s).

A power of attorney

An assignment of the invention to _____

A Preliminary Amendment

A verified statement to establish small entity status under 37 C.F.R.
§1.9 and §1.27.

The filing fee is calculated as follows:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT

	NUMBER FILED		NUMBER EXTRA*		RATE		FEE	
					SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTITY
Total Claims	17 - 20	=	0	X	\$ 9.00	\$ 18.00	=	\$ -0-
Independent Claims	5 - 3	=	2	X	\$ 39.00	\$ 78.00	=	\$ 156
Multiple Dependent Claims Presented:	X Yes		No		\$ 130.00	\$ 260.00	=	\$ 260
*If the difference in Col. 1 is less than zero, enter "0" in Col. 2					BASIC FEE		\$ 345	\$.690
					TOTAL FEE		\$	\$ 1,106

Christophe P.G. Gerald, et al.
U.S. Serial No.: Not Yet Known
Filed: Herewith
Letter of Transmittal
Page 2

A check in the amount of \$ 1,106.00 to cover the filing fee.

Please charge Deposit Account No. _____ in the amount of \$ _____.

The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the following or credit any over-payment to Account No. 03-3125:

Filing fees under 37 C.F.R. §1.16.

Patent application processing fees under 37 C.F.R. §1.17.


The issue fee set in 37 C.F.R. §1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. §1.311(b).

Three copies of this sheet are enclosed.

A certified copy of previously filed foreign application No. _____ filed in _____ on _____.
Applicant(s) hereby claim priority based upon this aforementioned foreign application under 35 U.S.C. §119.

Other (identify) 1 loose set of formal drawings, paper copy of sequence listing, computer readable diskette, Statement in Accordance with 37 C.F.R. §1.821(f), Information Disclosure Statement including form PTO-1449, Express Mail Certificate of Mailing bearing label no. EM 525 891 324 US dated March 29, 2000

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Christophe P.G. Gerald et al.
Serial No. : Not Yet Known
Filed : Herewith
For : DNA ENCODING MAMMALIAN NEUROPEPTIDE FF
(NPFF) RECEPTORS AND USES THEREOF

JC530 U.S. PTO
09/538036
03/29/00

1185 Avenue of the Americas
New York, New York 10036
March 29, 2000

Assistant Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

Sir:

**EXPRESS MAIL
CERTIFICATE OF MAILING
FOR THE ABOVE-IDENTIFIED APPLICATION**

"Express Mail" mailing label number: EM 525 891 324 US

Date of Deposit: March 29, 2000
I hereby certify that this paper or fee is being deposited
with the United States Postal Service "Express Mail Post
Office to Addressee" service under 37 C.F.R. §1.10 on the
date indicated above and is addressed to the Assistant
Commissioner for Patents, Washington, D.C. 20231.

Printed Name: John P. White

Respectfully submitted,


John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Christophe P.G. Gerald, et al.
Serial No. : Not Yet Known
Filed : Herewith
For : DNA ENCODING MAMMALIAN NEUROPEPTIDE FF
(NPFF) RECEPTORS AND USES THEREOF

jc530 U.S. PTO
09/538036
03/29/00

1185 Avenue of the Americas
New York, New York 10036
March 29, 2000


Assistant Commissioner for Patents
Washington, D.C. 20231

SIR:

**STATEMENT IN ACCORDANCE
WITH 37 C.F.R. §1.821(f) FOR
ABOVE-IDENTIFIED APPLICATION**

Pursuant to 37 C.F.R. §1.821(f), I hereby certify that the contents of the Sequence Listing enclosed herewith as **Exhibit A** and the contents of the computer readable form of the sequence listings are identical.

Respectfully submitted,


Jennifer H. Burdman
Registration No. 44,574
c/o Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400